Pharmaceutical - epidiolex

Filter

Current filters:

epidiolex

Popular Filters

GW shares rise on positive Epidiolex efficacy data

GW shares rise on positive Epidiolex efficacy data

18-06-2014

UK-based GW Pharmaceuticals has announced physician reports of efficacy and safety data from its investigational…

epidiolexGW PharmaceuticalsNeurologicalPharmaceuticalResearchUK

US FDA grants Fast Track designation for GW Pharma’s Epidiolex in Dravet syndrome

US FDA grants Fast Track designation for GW Pharma’s Epidiolex in Dravet syndrome

06-06-2014

The US Food and Drug Administration has granted Fast Track designation to UK-based GW Pharmaceuticals’…

epidiolexGW PharmaceuticalsPharmaceuticalRare diseasesRegulationTreatment of Dravet syndromeUSA

GW Pharma and New York State to initiate trials of cannabidiol in epilepsy

GW Pharma and New York State to initiate trials of cannabidiol in epilepsy

04-06-2014

UK-based GW Pharmaceuticals, a biopharmaceutical company focused on developing novel therapeutics from…

epidiolexGW PharmaceuticalsMedication-resistant epilepsyNeurologicalPharmaceuticalResearchUSA

GW Pharmaceuticals updates on cannabinoid pipeline

GW Pharmaceuticals updates on cannabinoid pipeline

17-03-2014

UK biopharma company GW Pharmaceuticals this morning provided an update on the company’s cannabinoid…

DiabetesepidiolexGW PharmaceuticalsGWP42004GWP42006NeurologicalPharmaceuticalResearchSativex

US orphan status for GW Pharma’s Epidiolex in Lennox-Gastaut syndrome

28-02-2014

UK-based GW Pharmaceuticals says that the Food and Drug Administration has granted orphan drug designation…

epidiolexGW PharmaceuticalsNeurologicalNorth AmericaPharmaceuticalRegulationUSA

GW Pharma revenues rise but 1st-qtr loss incurred

GW Pharma revenues rise but 1st-qtr loss incurred

05-02-2014

Shares of UK-based cannabis-based drug developer GW Pharmaceuticals fell 3,9% to 287.39 pence this morning,…

epidiolexFinancialGW PharmaceuticalsNeurologicalPharmaceuticalResearchSativex

Back to top